Amylyx Pharma Q3 loss narrows

Reuters11-06

Amylyx Pharma Q3 loss narrows

Overview

Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income
Company's cash position strengthened by $191 mln public offering, extending runway into 2028
Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026

Outlook

Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026
Topline data from LUCIDITY trial anticipated in Q3 2026
Commercial launch of avexitide anticipated in 2027, if approved

Result Drivers

Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Beat	-$0.37	-$0.47 (7 Analysts)
Q3 Net Income	Beat	-$34.39 mln	-$41.60 mln (8 Analysts)
Q3 Operating Income	Beat	-$36.03 mln	-$43.10 mln (9 Analysts)
Q3 Pretax Profit	Beat	-$34.39 mln	-$42.50 mln (6 Analysts)
Q3 Operating Expenses		$36.03 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $19.00, about 30.3% above its November 5 closing price of $13.24

Press Release: ID:nBw1MCSvVa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581006725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581006725","market":"nz","top_or_hot":-1,"title":"Amylyx Pharma Q3 loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amylyx Pharma Q3 loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income</p></li><li><p>Company's cash position strengthened by $191 mln public offering, extending runway into 2028</p></li><li><p>Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026</p></li><li><p>Topline data from LUCIDITY trial anticipated in Q3 2026</p></li><li><p>Commercial launch of avexitide anticipated in 2027, if approved</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.37</p></td><td><p>-$0.47 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$41.60 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$36.03 mln</p></td><td><p>-$43.10 mln (9 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$42.50 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$36.03 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Inc is $19.00, about 30.3% above its November 5 closing price of $13.24</p></li></ul><p>Press Release: <span>ID:nBw1MCSvVa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amylyx Pharma Q3 loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmylyx Pharma Q3 loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amylyx Pharma Q3 loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income</p></li><li><p>Company's cash position strengthened by $191 mln public offering, extending runway into 2028</p></li><li><p>Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026</p></li><li><p>Topline data from LUCIDITY trial anticipated in Q3 2026</p></li><li><p>Commercial launch of avexitide anticipated in 2027, if approved</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.37</p></td><td><p>-$0.47 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$41.60 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$36.03 mln</p></td><td><p>-$43.10 mln (9 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$42.50 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$36.03 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Inc is $19.00, about 30.3% above its November 5 closing price of $13.24</p></li></ul><p>Press Release: <span>ID:nBw1MCSvVa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0KB:1","article_id":"2581006725","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581006725","pubTimestamp":1762431601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amylyx Pharma Q3 loss narrowsOverviewAmylyx Q3 net loss narrows, beating analyst expectations for EPS and net incomeCompany's cash position strengthened by $191 mln public offering, extending runway i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals","BK4007":"制药"},"translate_title":"Amylyx Pharma第三季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":0.9},"content_text":"Amylyx Pharma Q3 loss narrowsOverviewAmylyx Q3 net loss narrows, beating analyst expectations for EPS and net incomeCompany's cash position strengthened by $191 mln public offering, extending runway into 2028Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026OutlookCompany expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026Topline data from LUCIDITY trial anticipated in Q3 2026Commercial launch of avexitide anticipated in 2027, if approvedResult DriversResearch and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSBeat-$0.37-$0.47 (7 Analysts)Q3 Net IncomeBeat-$34.39 mln-$41.60 mln (8 Analysts)Q3 Operating IncomeBeat-$36.03 mln-$43.10 mln (9 Analysts)Q3 Pretax ProfitBeat-$34.39 mln-$42.50 mln (6 Analysts)Q3 Operating Expenses$36.03 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $19.00, about 30.3% above its November 5 closing price of $13.24Press Release: ID:nBw1MCSvVaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581006725","isCrawlerRequest":true}